@Article{or.2026.080964,
AUTHOR = {Carlo Signorelli, Michele Basso, Annunziato Anghelone, Maria Alessandra Calegari, Alessandro Passardi, Chiara Gallio, Alessandro Bittoni, Jessica Lucchetti, Lorenzo Angotti, Emanuela Di Giacomo, Ina Valeria Zurlo, Cristina Morelli, Emanuela Dell’Aquila, Adele Artemi, Donatello Gemma, Domenico Cristiano Corsi, Alessandra Emiliani, Marta Ribelli, Federica Mazzuca, Giulia Arrivi, Federica Zoratto, Maria Grazia Morandi, Fiorenza Santamaria, Manuela Dettori, Antonella Cosimati, Rosa Saltarelli, Alessandro Minelli, Emanuela Lucci-Cordisco, Mario Giovanni Chilelli},
TITLE = {On-Treatment Grade 3–4 Neutropenia and Clinical Outcomes with Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: ReTrITA Real-World Evidence},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/27045},
ISSN = {1555-3906},
ABSTRACT = {<b>Background</b>: Trifluridine/tipiracil (T) is a standard treatment for refractory metastatic colorectal cancer (mCRC). In randomized trials, treatment-emergent neutropenia has been associated with improved outcomes, suggesting a potential link with drug activity. However, evidence from routine clinical practice remains limited. This sub-analysis of the multicenter ReTrITA study evaluated the association between severe neutropenia and clinical outcomes in a real-world setting. <b>Methods</b>: Patients with refractory mCRC treated with T within the ReTrITA cohort were included. Patients were stratified according to the occurrence of grade 3–4 neutropenia. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox models. <b>Results</b>: Among 843 patients, 271 (32.1%) developed grade 3–4 neutropenia. The occurrence of severe neutropenia was significantly associated with improved survival outcomes. Median OS was 10.9 months versus 7.6 months, HR 0.64; 95% CI, 0.55–0.75; <i>p</i> &lt; 0.0001), and median PFS was 4.3 months versus 3.3 months (HR 0.63; 95% CI, 0.55–0.73; <i>p</i> &lt; 0.0001) in patients with versus without neutropenia, respectively. <b>Conclusions</b>: In this large real-world cohort, grade 3–4 neutropenia during T treatment was associated with significantly improved OS and PFS, supporting its role as a potential on-treatment prognostic marker. Prospective studies are warranted to confirm these findings.},
DOI = {10.32604/or.2026.080964}
}